In this episode of SpreadLove in Organizations, Naji sits down with Hafedh Haddad, medical director and founder of B2G Life Sciences, to explore a career shaped by curiosity, courage, and meaningful encounters. From medical school in Tunisia to leading pioneering gene therapy clinical trials in France, Hafedh shares how openness to opportunity, rather than rigid planning, guided his journey across academia, biotech, and global clinical development.

Hafedh reflects on the power of encounters in shaping both career and character. He discusses his transition from preclinical research to clinical development, the launch of world-first gene therapy trials in rare diseases, and the founding of his consulting company. Throughout the conversation, he emphasizes the importance of trusting the journey, embracing change, and allowing purpose to evolve through experience.

At its core, this episode is about discovery, of the world, of science, and of oneself. Hafedh offers thoughtful insights on leadership, long-term vision versus adaptability, and the responsibility of working in rare and genetic diseases. It’s a powerful reminder that meaningful impact in healthcare often begins with curiosity and grows through humility, relationships, and a deep commitment to patients.

"Plan the bigger vision. Let the details unfold, and move with them."

MEET OUR GUEST Hafedh Haddad Founder & CEO @ B2G Life Sciences.

Hafedh is a medical doctor and holds a master’s degree in clinical research. He has 20 years of experience in clinical research and clinical development, with – among other specialties - a focus on rare and genetic diseases, oncology and biotherapies.

Early in his career, he has collaborated to a few preclinical research programs in neuromuscular disorders within academic laboratories in Paris. He later joined Généthon, a French biotech specialized in the development of advanced therapies, to set up and lead two world premiere gene therapy clinical trials in rare diseases (AAV based in vivo gene therapy in limb girdle muscular dystrophy type 2C and lentiviral ex vivo gene therapy in Wiskott-Aldrich Syndrome).

He founded B2G Life Sciences, a medical consulting company in 2011, and has since then worked on several clinical research projects and medical affairs missions for several companies including biotechs and big pharma as well as academic institutions in Europe and North Africa.

Hafedh is an entrepreneur in the healthcare sector with both a strategy and operation-focused mindset. He worked on the ideation and development of different projects including staffing and training, biobanks and MedTech projects.

Hafedh graduated from the Faculty of Medicine of Tunis (Tunisia) and University Pierre et Marie Curie (UPMC), Paris (France).